Cargando…

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer

Ovarian cancer can be cured in up to 90% of cases if diagnosed early. CA125, the most studied ovarian cancer biomarker, exhibits poor sensitivity for detecting early disease stages and low specificity to malignancy. RECAF, the alpha-fetoprotein receptor, is a wide-spectrum oncofetal antigen with cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tcherkassova, Janneta, Abramovich, Carolina, Moro, Rafael, Chen, Chen, Schmit, Ralph, Gerber, Angela, Moro, Ricardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131516/ https://www.ncbi.nlm.nih.gov/pubmed/21625941 http://dx.doi.org/10.1007/s13277-011-0186-1

Ejemplares similares

First report of the unique expression of RECAF (receptor for alfa feto-protein) in adult B-NHL/CLL patients
por: Sedky, Hebatallah Adel, et al.
Publicado: (2020)

Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis
por: Chen, Zhixiang, et al.
Publicado: (2020)

Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
por: Weiland, Florian, et al.
Publicado: (2012)

Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer
por: Gu, Zhuowei, et al.
Publicado: (2018)

Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer
por: Tang, Ying, et al.
Publicado: (2020)

Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer
por: Guo, Bingcheng, et al.
Publicado: (2019)

Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer
por: Chen, Jie-Ping, et al.
Publicado: (2019)

Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer
por: Ali, Fahmy T., et al.
Publicado: (2022)

The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer
por: Anastasi, Emanuela, et al.
Publicado: (2013)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

CA125 and Ovarian Cancer: A Comprehensive Review
por: Charkhchi, Parsa, et al.
Publicado: (2020)

Combined Evaluation of Preoperative Serum CEA and CA125 as an Independent Prognostic Biomarker in Patients with Early-Stage Cervical Adenocarcinoma
por: Huang, Genping, et al.
Publicado: (2020)

Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass
por: Partheen, Karolina, et al.
Publicado: (2011)

The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.
por: Fisken, J., et al.
Publicado: (1993)

Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative
por: Dunton, Charles J., et al.
Publicado: (2021)

The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study
por: Bai, Huimin, et al.
Publicado: (2016)

Serum CA125, CA199 and CEA Combined Detection for Epithelial Ovarian Cancer Diagnosis: A Meta-analysis
por: Guo, Junhong, et al.
Publicado: (2017)

Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer
por: Koh, Stephen Chee Liang, et al.
Publicado: (2012)

The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer
por: Zheng, Li-e, et al.
Publicado: (2016)

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
por: Dochez, Vincent, et al.
Publicado: (2019)

Novel ssDNA Ligand Against Ovarian Cancer Biomarker CA125 With Promising Diagnostic Potential
por: Tripathi, Pranav, et al.
Publicado: (2020)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

The Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer
por: Fayed, Salah T., et al.
Publicado: (1998)

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990)

The effect of CA125 on metastasis of ovarian cancer: old marker new function
por: Yuan, Qin, et al.
Publicado: (2017)

Diagnostic Utility of Combined CEA, CA15-3 and CA125 Biomarkers and Cytomorphology in Suspicious and Malignant Serosal Fluid
por: Rahemi, Zahra, et al.
Publicado: (2021)

A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients
por: Leandersson, Pia, et al.
Publicado: (2020)

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
por: Alegría-Baños, Jorge A., et al.
Publicado: (2021)

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
por: Rustin, G. J., et al.
Publicado: (1996)

TB Peritonitis Mistaken for Ovarian Carcinomatosis Based on an Elevated CA-125
por: Boss, Joseph D., et al.
Publicado: (2012)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer
por: Song, Jin, et al.
Publicado: (2023)

Ligand-based adoptive T cell targeting CA125 in ovarian cancer
por: Zhao, Haihong, et al.
Publicado: (2023)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer
por: Chiang, An Jen, et al.
Publicado: (2014)

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors
por: Chen, Fawen, et al.
Publicado: (2018)

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
por: Felder, Mildred, et al.
Publicado: (2014)

The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population
por: Barr, Chloe E., et al.
Publicado: (2022)

Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5gtr55q3u7t0calpmvij6te94m